Antares overactive bladder drug deal opens up S. Korea market

Antares Pharma (NYSE:AIS) has licensed its newly approved overactive bladder gel to South Korea pharmaceutical company Daewoong Pharmaceuticals Co. in a move that will bring the drug to the Asian market. Ewing, New Jersey-based Antares will receive undisclosed up-front payments, regulatory milestones and sales-based milestones, as well as royalties on net sales for the product, […]

Devices & Diagnostics

Antares inks licensing agreement with Pfizer

Antares Pharma (AMEX:AIS) has inked a licensing  agreement with Pfizer (NYSE:PFE) to provide one of its drug-delivery technologies to Pfizer’s consumer healthcare business arm for an unnamed product for North America. Pfizer, in New York, will be responsible for clinical development, manufacturing and commercialization of the product. Ewing, New Jersey-based Antares will receive up-front payments, […]


Phase 3 clinical trials for sex dysfunction gel fall short

A gel developed by Antares (AMEX:AIS) and licensed to BioSante Pharmaceuticals (NASDAQ:BPAX) to treat female sexual dysfunction failed two phase 3 clinical trials testing efficacy, according to a statement from BioSante. Initial analysis of the data from the trials showed that the tests “did not meet the co-primary or secondary endpoints,” the statement said. LibiGel […]